Illumina, Inc.

NASDAQ:ILMN

Medical - Diagnostics & Research

Healthcare
$210.01 +1.23%

+$1.95 today

Market cap
$31.75B
Beta
1.49
P/E (TTM)
28.9
EPS (TTM)
$5.58
52W Low $88.00High $177.22

Volume 1.63M

Average 1.65M

ILMN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Illumina, Inc.NASDAQ: ILMN

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 66.4%

Gross margin was 66.4% in Q2 FY2026, down 1.4 pp from a year earlier. On a trailing-twelve-month basis it was 66.8%, down 0.3 pp year over year. Over 3 fiscal years it widened by 1.9 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
66.4%+0.4 pp QoQ
Last fiscal yearDec 2025
66.7%+1.3 pp YoY
LTMJun 2026
66.8%-0.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.4 pp——
1 year+1.3 pp——
3 years+1.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
66.7%
Year-over-year change
+1.3pp

Gross Margin vs competitors

How ILMN compares with its peers on the latest reported figures

  • ILMN's LTM Jun 2026 gross margin of 66.8% is the 6th highest of the 11 companies compared; the peer median is 66.3%.
  • Its year-over-year change of -0.3 pp is the 8th highest of 11, against a peer median of +1.2 pp.
  • Over three fiscal years its change of +1.9 pp compares with a peer median of -0.5 pp.
ILMN Competitors Peer median
Gross Margin for ILMN and competitors
Company Period LTM level YoY 3-year change
TXG10x Genomics, Inc.LTM Sep 202671.9% +3.0 pp-7.6 pp
BLLNBillionToOne, Inc.LTM Jun 202671.3% +10.3 pp—
MYGNMyriad Genetics, Inc.LTM Mar 202670.0% -0.0 pp-0.3 pp
WGSGeneDx Holdings Corp.LTM Jun 202668.2% +1.0 pp+81.1 pp
SOPHSOPHiA GENETICS S.A.LTM Mar 202667.3% -0.8 pp-3.8 pp
ILMNIllumina, Inc.LTM Jun 202666.8% -0.3 pp+1.9 pp
NTRANatera, Inc.LTM Jun 202665.3% +2.4 pp+20.5 pp
GHGuardant Health, Inc.LTM Sep 202665.2% +1.4 pp-0.8 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
PACBPacific Biosciences of California, Inc.LTM Mar 202637.1% +20.9 pp-6.5 pp
PSNLPersonalis, Inc.LTM Mar 202613.7% -19.6 pp—
Peer median (excluding ILMN) 66.3%+1.2 pp-0.5 pp

Competitors are the stored peer set for ILMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.53B4.58B4.5B4.37B4.34B
Cost of Revenue1.37B1.61B1.76B1.51B1.45B
Gross Profit3.15B2.97B2.74B2.86B2.89B
Gross Margin69.7%64.8%60.9%65.4%66.7%
Research & Development1.19B1.32B1.35B1.17B951M
Selling, General & Admin2.09B1.3B1.61B1.09B1.08B
Operating Expenses3.28B7.15B3.81B3.69B2.03B
Depreciation & Amortization251M394M432M354M270M
EBITDA1.2B(3.92B)(608M)(725M)1.46B
EBITDA Margin26.4%-85.4%-13.5%-16.6%33.6%
Operating Income(123M)(4.18B)(1.07B)(833M)864M
Operating Margin-2.7%-91.2%-23.7%-19.1%19.9%
Interest Income011M58M46M40M
Interest Expense61M26M77M100M101M
Other Income / Expenses1.01B(157M)(48M)(346M)222M
Income Before Tax884M(4.34B)(1.12B)(1.18B)1.09B
Pre-Tax Margin19.5%-94.6%-24.8%-27.0%25.0%
Income Tax Expense122M68M44M44M236M
Net Income762M(4.4B)(1.16B)(1.22B)850M
Net Margin16.8%-96.1%-25.8%-28.0%19.6%
EPS (Basic)5.08(28.05)(7.35)(7.69)5.48
EPS (Diluted)5.05(28.05)(7.35)(7.69)5.45
Weighted Avg Shares150M157M158M159M155M
Weighted Avg Shares (Diluted)151M157M158M159M156M

Illumina, Inc.

NASDAQ:ILMN

Intrinsic Alpha fair value

Locked

Current Price

$210.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.